Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness.

Published

Journal Article

BACKGROUND:Optimal management of chronic medications for patients with life-limiting illness is uncertain. Medication deprescribing may improve outcomes in this population, but patient concerns regarding deprescribing are unclear. OBJECTIVE:The aim of this study was to quantify the perceived benefits and concerns of statin discontinuation among patients with life-limiting illness. DESIGN:Baseline data from a multicenter, pragmatic clinical trial of statin discontinuation were used. SETTING/SUBJECTS:Cognitively intact participants with a life expectancy of 1-12 months receiving statin medications for primary or secondary prevention were enrolled. MEASUREMENTS:Responses to a 9-item questionnaire addressing patient concerns about discontinuing statins were collected. We used Pearson chi-square tests to compare responses by primary life-limiting diagnosis (cancer, cardiovascular disease, other). RESULTS:Of 297 eligible participants, 58% had cancer, 8% had cardiovascular disease, and 30% other primary diagnoses. Mean (standard deviation) age was 72 (11) years. Fewer than 5% of participants expressed concern that statin deprescribing indicated physician abandonment. About one in five participants reported being told to take statins for the rest of their life (18%) or feeling that discontinuation represented prior wasted effort (18%). Many participants reported benefits of stopping statins, including spending less money on medications (63%), potentially stopping other medications (34%), and having a better quality of life (25%). More participants with cardiovascular disease as a primary diagnosis perceived that quality-of-life benefits related to statin discontinuation (52%) than participants with cancer (27%) or noncardiovascular disease diagnoses (27%) [p = 0.034]. CONCLUSION:Few participants expressed concerns about discontinuing statins; many perceived potential benefits. Cardiovascular disease patients perceived greater potential positive impact from statin discontinuation.

Full Text

Duke Authors

Cited Authors

  • Tjia, J; Kutner, JS; Ritchie, CS; Blatchford, PJ; Bennett Kendrick, RE; Prince-Paul, M; Somers, TJ; McPherson, ML; Sloan, JA; Abernethy, AP; Furuno, JP

Published Date

  • October 2017

Published In

Volume / Issue

  • 20 / 10

Start / End Page

  • 1098 - 1103

PubMed ID

  • 28520522

Pubmed Central ID

  • 28520522

Electronic International Standard Serial Number (EISSN)

  • 1557-7740

International Standard Serial Number (ISSN)

  • 1096-6218

Digital Object Identifier (DOI)

  • 10.1089/jpm.2016.0489

Language

  • eng